Promising disease product candidates for difficult to treat diseases

ANV221 - Targeting the Cancer Glycobiome 
(Not yet FDA/EU approved - for clinical awareness, research, and investor purposes only)

Several solid tumor cancers have been found to upregulate N-glycosylation to fuel one or more of their hallmark behaviors.  ANV221 is a novel drug candidate that interrupts this cycle in vivo models leading to:   

• Disruption of chronic proliferation signaling

• Activation of evolutionary conserved apoptosis (cell suicide) pathways

• Suppressing cell invasiveness, migration and metastasis

• Reversing stem like transformations, thus enhancing tumor vulnerability to other cytotoxic therapies

• Low observed toxicity

​

ANV221 was awarded Orphan Drug Designation for the treatment of Pancreatic Cancer by the FDA. 

"PDAC xenograft tumors were disappeared in two weeks."
- Michio Kurosu, PhD University of Tennessee Health Science Center 

Viruses and DPAGT1

Two virus families, coronavirus and flavivirus are known to upregulate N-glycosylation.  Read our white paper to learn how these viruses may respond to DPAGT1 inhibitors.